These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31133053)

  • 21. Anticipating IQOS market expansion in the United States.
    Abroms L; Levine H; Romm K; Wysota C; Broniatowski D; Bar-Zeev Y; Berg C
    Tob Prev Cessat; 2022; 8():04. PubMed ID: 35174298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
    Lempert LK; Bialous S; Glantz S
    Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Availability and Placement of Electronic Nicotine Delivery Systems at the Point-of-Sale.
    Wagoner KG; Song EY; King JL; Egan KL; Debinski B; Wolfson M; Spangler J; Sutfin EL
    Nicotine Tob Res; 2018 Jul; 20(8):1020-1024. PubMed ID: 29059443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IQOS Use and Interest by Sociodemographic and Tobacco Behavior Characteristics among Adults in the US and Israel.
    Levine H; Duan Z; Bar-Zeev Y; Abroms LC; Khayat A; Tosakoon S; Romm KF; Wang Y; Berg CJ
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 'I perceive it to be less harmful, I have no idea if it is or not:' a qualitative exploration of the harm perceptions of IQOS among adult users.
    East KA; Tompkins CNE; McNeill A; Hitchman SC
    Harm Reduct J; 2021 Apr; 18(1):42. PubMed ID: 33849549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Investigation of Influential Users in the Promotion and Marketing of Heated Tobacco Products on Instagram: A Social Network Analysis.
    Gu J; Abroms LC; Broniatowski DA; Evans WD
    Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolving IQOS packaging designs change perceptions of product appeal, uniqueness, quality and safety: a randomised experiment, 2018, USA.
    Lee JGL; Blanchflower TM; O'Brien KF; Averett PE; Cofie LE; Gregory KR
    Tob Control; 2019 Aug; 28(e1):e52-e55. PubMed ID: 31164489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Revolution or redux? Assessing IQOS through a precursor product.
    Elias J; Dutra LM; St Helen G; Ling PM
    Tob Control; 2018 Nov; 27(Suppl 1):s102-s110. PubMed ID: 30305324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low compliance and proliferation of IQOS purchase cues at points-of-sale: a comparative study before and after Israel's display ban.
    Bar-Zeev Y; Berg CJ; Khayat A; Abroms LC; Wang Y; Duan Z; LoParco CR; Cui Y; Elbaz D; Levine H
    Tob Control; 2024 Jun; ():. PubMed ID: 38862232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung Function in Users of a Smoke-Free Electronic Device With HeatSticks (iQOS) Versus Smokers of Conventional Cigarettes: Protocol for a Longitudinal Cohort Observational Study.
    Sharman A; Zhussupov B; Sharman D; Kim I; Yerenchina E
    JMIR Res Protoc; 2018 Nov; 7(11):e10006. PubMed ID: 30401669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke.
    Nabavizadeh P; Liu J; Havel CM; Ibrahim S; Derakhshandeh R; Jacob Iii P; Springer ML
    Tob Control; 2018 Nov; 27(Suppl 1):s13-s19. PubMed ID: 30206183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IQOS: examination of Philip Morris International's claim of reduced exposure.
    St Helen G; Jacob Iii P; Nardone N; Benowitz NL
    Tob Control; 2018 Nov; 27(Suppl 1):s30-s36. PubMed ID: 30158205
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Berthet A; Butty A; Rossier J; Sadowski IJ; Froidevaux P
    Sci Rep; 2022 Jun; 12(1):10314. PubMed ID: 35725999
    [No Abstract]   [Full Text] [Related]  

  • 34. Are retailers compliant with zoning regulations that ban tobacco sales near schools in Changsha, China?
    Wang L; Lu B; Wewers ME; Foraker RE; Xie M; Ferketich AK
    Tob Control; 2017 Jul; 26(4):446-451. PubMed ID: 27457789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IQOS Marketing Strategies and Expenditures in the United States From Market Entrance in 2019 to Withdrawal in 2021.
    Duan Z; Levine H; Romm KF; Bar-Zeev Y; Abroms LC; Griffith L; Wang Y; Khayat A; Cui Y; Berg CJ
    Nicotine Tob Res; 2023 Sep; 25(11):1798-1803. PubMed ID: 37338204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Content analysis of IQOS direct mail and email marketing in the US.
    Henderson KC; Kute NG; Popova L; Ashley DL; Spears CA; Churchill V; Weaver SR; Pechacek TF; Huang J
    Prev Med Rep; 2024 Feb; 38():102634. PubMed ID: 38375169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Household Surveys in the General Population and Web-Based Surveys in IQOS Users Registered at the Philip Morris International IQOS User Database: Protocols on the Use of Tobacco- and Nicotine-Containing Products in Germany, Italy, and the United Kingdom (Greater London), 2018-2020.
    Sponsiello-Wang Z; Langer P; Prieto L; Dobrynina M; Skiada D; Camille N; Weitkunat R; Lüdicke F
    JMIR Res Protoc; 2019 May; 8(5):e12061. PubMed ID: 31094340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IQOS marketing strategies in the USA before and after US FDA modified risk tobacco product authorisation.
    Berg CJ; Romm KF; Bar-Zeev Y; Abroms LC; Klinkhammer K; Wysota CN; Khayat A; Broniatowski DA; Levine H
    Tob Control; 2023 Jul; 32(4):418-427. PubMed ID: 34667105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of FDA endorsement and modified risk versus exposure messaging in IQOS ads: a randomised factorial experiment among US and Israeli adults.
    Berg CJ; Duan Z; Wang Y; Thrasher JF; Bar-Zeev Y; Abroms LC; Romm KF; Khayat A; Levine H
    Tob Control; 2024 Mar; 33(e1):e69-e77. PubMed ID: 36428095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.